Portal de investigación
Outcomes of 544 Patients with t(6;9)/DEK::NUP214 acute myeloid leukemia undergoing allogeneic stem cell transplantation: an EBMT study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP)
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Andreozzi F.
- Galimard J.-E.
- Maertens J.
- Aljurf M.
- Clesham K.
- Maury S.
- Loron S.
- Passweg J.
- Schroeder T.
- Salmenniemi U.
- van Gorkom G.
- Peffault de Latour R.
- von dem Borne P.A.
- Locatelli F.
- Wynn R.F.
- Dalle J.-H.
- Esteve J.
- Nagler A.
- Kleinschmidt K.
- Mohty M.
- Kalwak K.
- Ciceri F.
Grupos
Abstract
Acute myeloid leukemia (AML) with translocation (6;9)(p23;q34) is a rare and high-risk disease, frequently co-occurring with FLT3-ITD alteration. We retrospectively analyzed 544 patients with t(6;9) AML undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) and reported to the EBMT registry, between 2000 and 2022. At 2-years, overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), non-relapse mortality (NRM) and GVHD-free/relapse-free survival (GRFS) were 65.7%, 59.1%, 23.0%, 17.9% and 45.6% respectively. The 431 patients transplanted in first complete remission (CR1) had more favorable OS (71.7%), LFS (65.8%) and RI (18.2%). Pediatric and adolescent/young adult (AYA, = 39 years) patients in CR1 had improved outcomes. In patients = 40 years old, OS, LFS, and NRM gradually worsened, whereas significant increase in RI and decrease in GRFS were observed after 53 years. In a matched-pair analysis performed on 76 FLT3-ITD positive and 76 negative CR1 patients, FLT3-ITD was associated with an approximately three-fold higher RI risk, without differences in OS. In conclusion, allo-HSCT in t(6;9) AML provides relatively favorable outcomes especially when performed in CR1. Pediatric and AYA patients derived the greatest benefit from transplant. FLT3-ITD positivity remains a relevant risk factor for relapse, though without impact on OS. © The Author(s), under exclusive licence to Springer Nature Limited 2026.
Datos de la publicación
- ISSN/ISSNe:
- 0268-3369, 1476-5365
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 42020760
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 0,998 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
BONE MARROW TRANSPLANTATION SPRINGERNATURE
Documentos
- No hay documentos
Filiaciones
Cita
Andreozzi F,Galimard J-E,Maertens J,Aljurf M,Clesham K,SANZ J,Maury S,Loron S,Passweg J,Schroeder T,Salmenniemi U,van G,Peffault de Latour R,von dem Borne PA,Locatelli F,Wynn RF,Dalle J-H,Esteve J,Nagler A,Kleinschmidt K,Mohty M,Kalwak K,Ciceri F. Outcomes of 544 Patients with t(6;9)/DEK::NUP214 acute myeloid leukemia undergoing allogeneic stem cell transplantation: an EBMT study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP). Bone Marrow Transplant. 2026. 61. (7):p. 838-846. IF:5,100. (1).